Carnegie Capital Asset Management, LLC Editas Medicine, Inc. Transaction History

Carnegie Capital Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 12, 2021	SELL	$39.71 - $90.58 $138,151 - $315,127	-3,479 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$27.07 - $84.35 $94,176 - $293,453	3,479 New	3,479 $244,000
Q1 2020 May 08, 2020	SELL	$14.88 - $32.78 $544,459 - $1.2 Million	-36,590 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$19.49 - $32.63 $197,823 - $331,194	-10,150 Reduced 21.72%	36,590 $1.08 Million
Q3 2019 Nov 20, 2019	BUY	$22.49 - $26.81 $151,807 - $180,967	6,750 Added 16.88%	46,740 $1.06 Million

Q2 2019 Jul 24, 2019	BUY	$20.48 - $27.76 $818,995 - $1.11 Million	39,990 New	39,990 $989,000
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $837,649 - $1.46 Million	-46,050 Closed	0 $0
Q3 2018 Nov 27, 2018	BUY	$27.65 - $38.39 $255,209 - $354,339	9,230 Added 25.07%	46,050 $1.33 Million
Q2 2018 Aug 16, 2018	SELL	$31.4 - $41.01 $169,560 - $221,454	-5,400 Reduced 12.79%	36,820 $1.09 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $78,180 - $115,489	2,620 Added 6.62%	42,220 $1.49 Million
Q4 2017 Feb 12, 2018	BUY	$21.89 - $31.34 $866,844 - $1.24 Million	39,600	39,600 $1.45 Million

243

69.3M

564K

428K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $312M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Carnegie Capital Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Carnegie Capital Asset Management, LLC with notifications on news.